Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee

With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee. MTX-071 (resinife... Biopharmaceuticals, Mergers & Acquisitions Grünenthal, Mestex AG, resiniferatoxin, osteoarthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news